The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

YunJung  Kim

No Relationships to Disclose

Boram  Ok

No Relationships to Disclose

Inkeun  Park

No Relationships to Disclose

Baek-Yeol  Ryoo

No Relationships to Disclose

Kyu-Pyo  Kim

Travel, Accommodations, Expenses - Agios; Roche/Genentech; Roche/Genentech

Changhoon  Yoo

Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; SERVIER

Research Funding - AstraZeneca; Bayer; SERVIER